LIFNanoRx is a nano-bio-med company focused on treatment of Multiple Sclerosis (MS), a disabling incurable auto-immune inflammatory disease of the central nervous system (CNS) commonly affecting young adults. LIF – short for Leukaemia Inhibitory Factor – is a critical stem cell factor that has unique biological properties: these not only promote tissue repair but also suppress disease-linked inflammation. These therapeutic properties are harnessed in LIFNanoRx’s targeted medicinal nanoparticle – ‘LIFNano’ – providing a safe, cell-free, drug-free and potentially curative approach to MS. The technology is patented and LIFNanoRx holds worldwide exclusive licence in exploitation of LIF using their NanoMed platform technology.
Get in touch
News about LIFNano
A new project to tackle the most challenging cancers includes the involvement of Dr Su Metcalfe, whose venture LIFNanoRx is supported by the Accelerate Cambridge programme at Cambridge Judge.
Programme news
‘Big difference’ ventures
Eight ventures with Cambridge Judge connections were honoured in the first Cambridge Independent Entrepreneurial Science and Technology Awards.
Dr Su Metcalfe, Founding Director and Chief Scientist Officer of LIFNano Therapeutics, talks about her journey from scientist to entrepreneur.